Olamufloxacin. Hokuriku Seiyaku.
Hokuriku is developing olamufloxacin, a quinolone antibiotic that inhibits DNA gyrase, for the potential treatment of various types of bacterial infection. It has reached late phase II clinical trials. An intravenous formulation is also under investigation [277817].
Charles University Hospital, Department of Ophthalmology, 500 05 Hradec, Kralove, Czech Republic. kvasnicka@lfhk.cuni.cz
N
N
Jiraskova
D000818:Animals; D000890:Anti-Infective Agents / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D024841:Fluoroquinolones; D006801:Humans; D015363:Quinolones / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D013329:Structure-Activity Relationship
D000890:Anti-Infective Agents; D015507:Drugs, Investigational; D024841:Fluoroquinolones; D015363:Quinolones; C106426:olamufloxacin